[Synthetic antimalarials and skin].
Ribrioux
A
A
Service de Dermatologie, Hôpital Saint-Louis, Paris.
D000962:Antimalarials / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003882:Dermatomyositis / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology; D005128:Eye Diseases / Q000139:chemically induced*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy; D008247:Lysosomes / Q000187:drug effects; D009135:Muscular Diseases / Q000139:chemically induced; D010787:Photosensitivity Disorders / Q000188:drug therapy; D010859:Pigmentation Disorders / Q000139:chemically induced; D011537:Pruritus / Q000139:chemically induced; D011803:Quinine / Q000031:analogs & derivatives; D012507:Sarcoidosis / Q000188:drug therapy; D012867:Skin / Q000187:drug effects; D012871:Skin Diseases / Q000139:chemically induced*
D000962:Antimalarials; D011803:Quinine
Antipaludéens de synthèse et peau.